Development of V2-deleted trimeric envelope vaccine candidates from human immunodeficiency virus type 1 (HIV-1) subtypes B and C.
The urgent need for a vaccine against HIV/AIDS requires that multiple strategies be employed and evaluated in a clinical setting. V2-loop deleted trimeric envelope (Env) immunogens (protein and DNA) from subtypes B and C human immunodeficiency virus type 1 (HIV-1) strains were produced for ongoing and future clinical evaluations with other HIV antigens, adjuvants and deliveries.
Barnett
Susan W
SW
Vaccines Research Department, Chiron Corporation, 4560 Horton Street, Emeryville, CA 94608, USA. susan_barnett@chiron.com
Srivastava
Indresh K
IK
Ulmer
Jeffrey B
JB
Donnelly
John J
JJ
Rappuoli
Rino
R
D016915:AIDS Vaccines / Q000235:genetics / Q000276:immunology*; D000818:Animals; D017321:Clinical Trials, Phase I as Topic; D004353:Drug Evaluation, Preclinical; D004797:Enzyme-Linked Immunosorbent Assay; D015686:Gene Products, env / Q000737:chemistry / Q000235:genetics / Q000276:immunology*; D015483:HIV Antibodies / Q000097:blood*; D015658:HIV Infections / Q000517:prevention & control; D015497:HIV-1 / Q000145:classification / Q000235:genetics / Q000276:immunology*; D006801:Humans; D009500:Neutralization Tests; D011817:Rabbits; D019444:Vaccines, DNA / Q000235:genetics / Q000276:immunology; D014614:Vaccines, Synthetic / Q000235:genetics / Q000276:immunology; D054299:env Gene Products, Human Immunodeficiency Virus
D016915:AIDS Vaccines; D015686:Gene Products, env; D015483:HIV Antibodies; D019444:Vaccines, DNA; D014614:Vaccines, Synthetic; D054299:env Gene Products, Human Immunodeficiency Virus; C097729:gp140 envelope protein, Human immunodeficiency virus 1